Mass action drives the serum homeostasis of metabolites. Recent developments in biofluid metabolomics suggest the potential to harness these changes using small volumes of blood to diagnose, monitor, and risk stratify patients with cancer. This current study may represent a complementary technology to circulating tumor DNA detection.

Original languageEnglish
Pages (from-to)1477-1478
Number of pages2
JournalClinical Cancer Research
Issue number8
StatePublished - Apr 15 2022


Dive into the research topics of 'In an Era of ctDNA, Is Metabolomics the New Kid on the Block?'. Together they form a unique fingerprint.

Cite this